Pharma major Zydus Cadila on Thursday informed that the company has received final approval from the US drug regulator to market Potassium Citrate ER Tablets used in the prevention of kidney stones.
In a statement, the company informed that it has received final approval from US Food and Drug Administration (USFDA) to market Potassium Citrate ER Tablets 5, 10 and 15 mEq.
The estimated sales in 2014 for Potassium Citrate ER Tablets is USD 131.7 million, as per IMS, the company informed.
The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in fiscal 2003-04.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.